SJG-136
| Title | Journal |
|---|---|
| Small molecule drugs - optimizing DNA damaging agent-based therapeutics. | Current opinion in pharmacology 20120801 |
| Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats. | Cancer chemotherapy and pharmacology 20110901 |
| Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110601 |
| The development of pyrrolobenzodiazepines as antitumour agents. | Expert opinion on investigational drugs 20110601 |
| A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. | Cancer chemotherapy and pharmacology 20100401 |
| Synthesis of a novel C2/C2'-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate. | Bioorganic & medicinal chemistry letters 20091115 |
| The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links. | Journal of the American Chemical Society 20090930 |
| Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090315 |
| Remarkable enhancement in the DNA-binding ability of C2-fluoro substituted pyrrolo[2,1-c][1,4]benzodiazepines and their anticancer potential. | Bioorganic & medicinal chemistry 20090215 |
| ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136. | The pharmacogenomics journal 20080801 |
| An asymmetric C8/C8'-tripyrrole-linked sequence-selective pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer DNA interstrand cross-linking agent spanning 11 DNA base pairs. | Bioorganic & medicinal chemistry letters 20080315 |
| An assay combining high-performance liquid chromatography and mass spectrometry to measure DNA interstrand cross-linking efficiency in oligonucleotides of varying sequences. | Analytical biochemistry 20080301 |
| Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. | Journal of mass spectrometry : JMS 20080101 |
| Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells. | British journal of cancer 20070716 |
| The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare. | International journal of oncology 20061201 |
| DNA interstrand crosslinking agents: synthesis, DNA interactions, and cytotoxicity of dimeric achiral seco-amino-CBI and conjugates of achiral seco-amino-CBI with pyrrolobenzodiazepine (PBD). | Bioorganic & medicinal chemistry letters 20061101 |
| Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates. | Journal of medicinal chemistry 20060907 |
| LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501). | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060807 |
| Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling. | Molecular cancer therapeutics 20060601 |
| AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. 14-18th November 2005, Philadelphia, PA, USA. | IDrugs : the investigational drugs journal 20060101 |
| Direct liquid chromatography determination of the reactive imine SJG-136 (NSC 694501). | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050805 |
| Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136. | European journal of cancer (Oxford, England : 1990) 20050801 |
| Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies. | Biochemistry 20050322 |
| Synthesis of fluorinated analogues of SJG-136 and their DNA-binding potential. | Bioorganic & medicinal chemistry letters 20041115 |
| SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. | Cancer research 20040915 |
| SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations. | Cancer research 20040915 |
| The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill. | Cancer research 20040915 |
| Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent. | Investigational new drugs 20040801 |
| Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer. | Bioorganic & medicinal chemistry letters 20011105 |
| Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. | Journal of medicinal chemistry 20010301 |